CD46 and lymphoma: Targeting of the complement regulatory function of CD46 with mutant proteins derived from adenovirus Ad35 that bind to CD46 with very high affinity enhances response to Rituximab, an anti-CD20 antibody in lymphomas in non-human primates [100].